VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
VaxCT
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

PDTRP-MUC1-Calix[4,8]arene-Pam?Cys-Ser Self-Adjuvant Vaccines (Tetravalent and Octavalent)
Vaccine Information
  • Vaccine Name: PDTRP-MUC1-Calix[4,8]arene-Pam?Cys-Ser Self-Adjuvant Vaccines (Tetravalent and Octavalent)
  • Target Pathogen: Cancer
  • Target Disease: Cancer
  • Type: Conjugate vaccine
  • Status: Research
  • Host Species for Licensed Use: Mouse
  • Antigen: MUC1 [Ref6855:Geraci et al., 2013, (Spadaro et al., 2020)
  • Immunization Route: Intraperitoneal injection (i.p.)
  • Description: Synthetic multiepitope conjugate vaccines consisting of four (tetravalent, calix[4]arene scaffold) or eight (octavalent, calix[8]arene scaffold) copies of the PDTRP immunodominant B-cell epitope from the MUC1 core sequence, covalently conjugated to calixarene platforms with integrated Pam?Cys-Ser (P3CS) TLR2 agonist as a self-adjuvant. The vaccines target tumor-associated MUC1, a membrane-bound glycoprotein overexpressed in aberrant or underglycosylated form in breast, ovarian, prostate, and other epithelial cancers. PDTRP represents the exposed naked peptide core in underglycosylated cancer-associated MUC1. Vaccination stimulates anti-MUC1 IgG antibody production through multivalent B-cell receptor cross-linking. The octavalent construct produces 2-fold higher anti-PDTRP IgG titers compared to the tetravalent construct (5120 vs 2560, p<0.05), attributed to greater conformational flexibility, extended epitope presentation, and superior electrostatic complementarity. Controls lacking PDTRP produced no anti-MUC1 IgG, confirming epitope essentiality. Induced antibodies recognize native MUC1 epitopes on MCF-7 human breast cancer cells, validating functional antibody production [Ref6855:Geraci et al., 2013, (Spadaro et al., 2020).
Host Response
References
Spadaro et al., 2020: Spadaro A, Basile L, Pappalardo M, Bonaccorso C, Rao M, Ronsisvalle S, Granata G, Guccione S. Quantum Chemical and Molecular Dynamics Studies of MUC1 Calix[4,8]arene Scaffold Based Anticancer Vaccine Candidates. Journal of chemical information and modeling. 2020; 60(10); 5162-5171. [PubMed: 32818373].